The original disclosure in Japanese was released on July 27, 2016 at 15:30 (GMT+9)

Consolidated Financial Statements for the First Quarter Ended June 30, 2016
FY2017 (April 1, 2016 - March 31, 2017) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (1st section)
Code number: 2531
URL: http://www.takara.co.jp/
Company representative: Toshio Kakimoto, President
Contact: Takuya Kakemi, General Manager of Investor Relations Dept.
TEL : (075)241-5124

Quarterly statement filing date (as planned): August 8, 2016

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the three months ended June 30, 2016 (April 1, 2016 - June 30, 2016)

(1) Operating results

Note: Percentages indicated changes from the previous fiscal year.

	Three months ended June 30, 2016		Three months ended June 30, 2015	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	52,311	2.7	50,938	1.8
Operating income (loss)	1,630	151.0	649	(45.1)
Ordinary income (loss)	1,998	88.3	1,061	(28.6)
Net income (loss) attributable to owners of the parent	1,084	63.7	662	(18.4)
Net income (loss) per share (Yen)	5.39		3.29	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income	(3,242)	-	(357)	-

(2) Financial position

	As of June 30, 2016	As of March 31, 2016
	(Millions of yen)	(Millions of yen)
Total assets	245,681	253,253
Net assets	150,398	156,148
Equity ratio (%)	50.9	51.5
(Reference) Equity	125,170	130,386

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2016	Year ending March 31, 2017	Year ending March 31, 2017 (Forecast)
First quarter end	-	-	
Second quarter end	-		-
Third quarter end	-		-
Year end	12.00		12.00
Annual	12.00		12.00

Note: Correction of dividend forecast from the most recent dividend forecast : No
The year-end dividend for FY2016 include a commemorative dividend of ¥1.00

3. Forecast for the year ending March 31, 2017 (April 1, 2016 - March 31, 2017)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ending September 30, 2016		Year ending March 31, 2017	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	107,900	0.9	232,000	2.9
Operating income (loss)	3,800	(2.1)	12,000	2.7
Ordinary income (loss)	4,000	(7.6)	12,850	0.1
Net income (loss) attributable to owners of the parent	2,000	(20.8)	7,080	0.3
Net income per share (Yen)	9.94		35.18	

Note: Correction of financial forecast from the most recent financial forecast : No

4. Others

(1) Material changes in subsidiaries during this period
(Changes in scope of consolidations resulting from change is subsidiaries) : No

(2) Applying of specific accounting of the consolidated quarterly financial statements : No

(3) Changes in accounting policies, accounting estimates and retrospective restatement

1) Changes based on revisions of accounting standard : Yes
2) Changes other than ones based on revisions of accounting standard : No
3) Changes in accounting estimates : No
4) Restatement : No

(4) Number of outstanding shares (common stock)

1) Number of outstanding shares at year end (Treasury stocks are included)

As of June 30, 2016 : 217,699,743
As of March 31, 2016 : 217,699,743

2) Number of treasury stocks at year end

As of June 30, 2016 : 16,475,431
As of March 31, 2016 : 16,475,391

3) Average number of outstanding shares

Three months ended June 30, 2016 : 201,224,342
Three months ended June 30, 2015 : 201,225,603

Contents of the attached document

1. Qualitative Information for the Three Months Ended June 30, 2016 ---------- 2
   (1) Consolidated Financial Results ---------- 2
   (2) Consolidated Financial Position ---------- 3
   (3) Qualitative Information Regarding Consolidated Forecasts ---------- 3
2. Summary Information (Notes)---------- 4
   (1) Change in Accounting Policies and Changes and Retrospective Restatement of Accounting Estimates---- 4
   (2) Additional Information---------- 4
3. Consolidated Quarterly Financial Statements ---------- 5
   (1) Consolidated Quarterly Balance Sheets ---------- 5
   (2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income (For the Three Months Ended June 30, 2016and 2015) ---------- 7
   Consolidated Quarterly Statements of Income (For the Three Months Ended June 30, 2016 and 2015) --- 7
   Consolidated Quarterly Statements of Comprehensive Income (For the Three Months Ended June 30, 2016 and 2015) ---------- 8
   (3) Notes on Consolidated Quarterly Financial Statements ---------- 9
   (Notes on Premise of Going Concern) ---------- 9
   (Notes on Material Changes in Shareholders' Equity) ---------- 9
   (Segment Information) ---------- 9

Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Three Months Ended June 30, 2016

(1) Consolidated Financial Results

In the three months ended June 30, 2016, although the Japanese economy maintained a moderate recovery as the hiring and income environment improved, personal spending remained weak.

On the other hand, overseas, while the American economy continued on a recovery path, there was continued uncertainty for the future of the global economy caused by the slowdown in emerging country economies, the Brexit issue in the U.K. and other issues.

Under these economic circumstances, moving into the final fiscal year of the Takara Group Medium-Term Management Plan FY2017, which is the second step of efforts toward achieving the Takara Group Vision 2020, our long-term vision, the Group continued to make efforts to improve domestic business profitability and to expand and grow our overseas business while working on steady business activities with aim of transforming into a well-balanced business structure that can hold up well to business environment changes by accelerating growth in our Biomedical Business.

As a result, in the three months ended June 30, 2016, net sales were up by 2.7% year on year to ¥52,311 million. Gross profit rose 6.6% year on year to ¥20,919 million. Operating income increased by 151.0% year on year to ¥1,630 million while ordinary income rose 88.3% year on year to ¥1,998 million. Net income attributable to owners of the parent increased by 63.7% year on year to ¥1,084 million.

Results by business segment were as follows.

[Takara Shuzo Group]

For alcoholic beverages, in the three months ended June 30, 2016, while sales of shochu declined, sales of sake were in line with the same period of the previous fiscal year, and sales of light-alcohol refreshers increased as sales of Takara Shochu High Ball remained robust.

As sales of other alcoholic beverages such as whiskey also rose, sales of alcoholic beverages overall increased.

In the Seasonings Business, sales increased due to healthy sales of mirin and cooking sake while sales of raw alcohol, etc. and transportation sales declined.

In the Japanese Food Wholesale Business in overseas markets, sales at FOODEX S.A.S. (France), Cominport Distribución S.L. (Spain), and Tazaki Foods Ltd (U.K.) increased.

As a result, net sales for the Takara Shuzo Group rose 2.0% year on year to ¥45,124 million. Cost of sales increased by 0.5% to ¥28,622 million. As a result, gross profit rose 4.7% year on year to ¥16,501 million. SG&A expenses were up by 1.8% year on year to ¥15,658 million due to an increase in promotion expenses and transportation expenses. Accordingly, the Takara Shuzo Group recorded operating income up 121.8% year on year to ¥843 million in the three months ended June 30, 2016.

[Takara Bio Group]

Net sales for the three months ended June 30, 2016 increased by 9.5% year on year to ¥6,306 million because sales of mainstay research reagents significantly outperformed the same period of the previous fiscal year. Cost of sale was unchanged year on year at ¥2,439 million as the cost rate fell due to changes in the structure of sales for each product and other factors. Consequently, gross profit increased by 16.4% year on year to ¥3,866 million. SG&A expenses were roughly in line with the previous fiscal year up 0.4% year on year to ¥3,223 million as personnel expenses rose although research and development expenses declined. As a result, the Takara Bio Group recorded operating income up 476.3% year on year to ¥643 million in the three months ended June 30, 2016.

[Takara Healthcare]

Net sales for the three months ended June 30, 2016 fell by 4.2% year on year to ¥457 million due to falling sales of OEM cosmetics. Cost of sales was down by 15.5% year on year to ¥204 million. Consequently, gross profit increased by 7.2% year on year to ¥253 million. SG&A expenses were up by 18.7% year on year to ¥277 million, mainly due the increase in advertising expenses. As a result, Takara Healthcare recorded an operating loss of ¥24 million, compared to operating income of ¥2 million recorded in the same period of the previous fiscal year.

[Other]

Net sales of business segments other than the reported segments for the three months ended June 30, 2016 increased by 1.4% year on year to ¥1,304 million. Cost of sales fell by 1.6% year on year to ¥1,120 million. Consequently, gross profit increased by 23.7% year on year to ¥183 million. SG&A expenses were down by 6.7% year on year to ¥157 million. As a result, operating income of ¥25 million was recorded, compared to a ¥20 million operating loss recorded in the same period of the previous fiscal year.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2015, to June 30, 2015)	Period under Review (from April 1, 2016, to June 30, 2016)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo Group			
Shochu	14,323	14,128	98.6
Sake	4,503	4,516	100.3
Light-alcohol refreshers	6,876	7,300	106.2
Other alcoholic beverages	3,173	3,381	106.5
Alcoholic beverages total	28,877	29,327	101.6
Hon Mirin	3,332	3,464	104.0
Other seasonings	2,103	2,259	107.4
Seasonings total	5,435	5,724	105.3
Raw alcohol, etc.	1,902	1,769	93.0
Transportation	3,012	2,662	88.4
Japanese Food Wholesales Business in overseas markets	4,646	5,300	114.1
Other	357	340	95.3
Total	44,231	45,124	102.0
Takara Bio Group	5,761	6,306	109.5
Takara Healthcare	478	457	95.8
Other	1,286	1,304	101.4
Sales not allocated to business segments and intersegment transactions	(818)	(881)	-
Total	**50,938**	**52,311**	**102.7**

Note: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position

Total assets stood at ¥245,681 million as of June 30, 2016, down by ¥7,571 million from March 31, 2016. Current assets stood at ¥153,679 million, down by ¥5,394 million. This decrease primarily resulted from a decline of ¥1,939 million in notes and accounts receivable- trade and a decline of ¥3,328 million in securities.

Non-current assets decreased by ¥2,177 million from the end of the previous fiscal year to ¥92,002 million. The main factors were decreases of ¥806 million in property, plant and equipment, ¥815 million in intangible assets, and ¥446 million in investment securities.

Total liabilities amounted to ¥95,283 million as of June 30, 2016, down by ¥1,820 million from March 31, 2016. Current liabilities rose ¥3,565 million from the end of the previous fiscal year to ¥51,213 million. This was primarily due to a ¥5,000 million increase in current portion of bonds and a ¥1,150 million decrease in notes and accounts payable – trade.

Non-current liabilities declined ¥5,386 million from the end of the previous fiscal year to ¥44,069 million. This was primarily due to a ¥5,000 million decrease resulting from the transfer of bonds to current liabilities.

Net assets stood at ¥150,398 million as of June 30, 2016, down ¥5,750 million from the end of the previous fiscal year. The main factors were declines of ¥1,330 million in retained earnings and ¥3,101 million in foreign currency translation adjustment.

(3) Qualitative Information Regarding Consolidated Forecasts

The consolidated performance for the three months ended June 30, 2016 exceeded initial forecasts. Nevertheless, the Company has not revised the consolidated forecasts for the six months ending September 30, 2016 or for the fiscal year ending March 31, 2017 that were released on May 9, 2016 because the proportion of the Group's annual income accounted for by income in the first quarter of the fiscal year is relatively low.

2. Summary Information (Notes)

(1) Change in Accounting Policy and Retrospective Restatement of Accounting Estimates

(Change in Accounting Policy)

(Application of Practical Solution on a change in depreciation method due to Tax Reform 2016)

In the three month period ended June 30, 2016, the Company applied Practical Solution on a change in depreciation method due to Tax Reform 2016 (PITF No. 32, June 17, 2016) following the revision of the Corporation Tax Act, and changed the method of depreciation for structures and facilities attached to buildings acquired on and after April 1, 2016 from the declining-balance method to the straight-line method.

The impact of this change on operating income, ordinary income, and profit before income taxes and minority interests for the three month period ended June 30, 2016 is immaterial.

(2) Additional Information

(Application of Revised Implementation Guidance on Recoverability of Deferred Tax Assets)

The Company has been applying the Revised Implementation Guidance on Recoverability of Deferred Tax Assets (ASBJ Guidance No. 26 of March 28, 2016) from the beginning of the three month period ended June 30, 2016.

3. Consolidated Quarterly Financial Statements

(1) Consolidated Quarterly Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2016	As of June 30, 2016
Assets		
Current assets		
Cash and deposits	38,386	37,676
Notes and accounts receivable-trade	53,602	51,662
Securities	28,238	24,909
Merchandise and finished goods	29,739	29,085
Work in process	1,077	1,207
Raw materials and supplies	3,401	2,996
Other	4,859	6,365
Allowance for doubtful accounts	(231)	(224)
Total current assets	159,073	153,679
Noncurrent assets		
Property, plant and equipment	53,065	52,258
Intangible assets		
Goodwill	6,975	6,504
Other	4,035	3,691
Total intangible assets	11,010	10,195
Investments and other assets		
Investment securities	24,747	24,301
Other	5,468	5,339
Allowance for doubtful accounts	(112)	(91)
Total investments and other assets	30,103	29,549
Total noncurrent assets	94,179	92,002
Total assets	253,253	245,681

(Millions of Yen)

	As of Mar. 31, 2016	As of June 30, 2016
Liabilities		
Current liabilities		
Notes and accounts payable-trade	15,201	14,051
Short-term loans payable	4,994	4,806
Current portion of bonds	-	5,000
Accrued alcohol tax	7,855	7,308
Accrued expenses	4,965	4,065
Income taxes payable	2,307	992
Provision for bonuses	2,235	3,405
Other provision	1,954	2,195
Other	8,133	9,387
Total current liabilities	47,648	51,213
Noncurrent liabilities		
Bonds payable	20,000	15,000
Long-term loans payable	10,255	10,247
Net defined benefit liability	8,544	8,580
Long-term deposits received	5,379	5,362
Other	5,277	4,878
Total noncurrent liabilities	49,456	44,069
Total liabilities	97,104	95,283
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	1,879	1,879
Retained earnings	113,663	112,333
Treasury stock	(9,938)	(9,938)
Total shareholders' equity	118,830	117,500
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	6,822	6,548
Deferred gains or losses on hedges	(445)	(949)
Foreign currency translation adjustment	5,548	2,446
Remeasurements of defined benefit plans	(370)	(376)
Total accumulated other comprehensive income	11,555	7,670
Noncontrolling interests	25,762	25,227
Total net assets	156,148	150,398
Total liabilities and net assets	253,253	245,681

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income

(Consolidated Statements of Income)
(For the Three Months Ended June 30, 2016 and 2015)

(Millions of Yen)

	FY2016 (Apr. 1, 2015 – June 30, 2015)	FY2017 (Apr. 1, 2016 – June 30, 2016)
Net sales	50,938	52,311
Cost of sales	31,323	31,391
Gross profit	19,615	20,919
Selling, general and administrative expenses	18,966	19,289
Operating income	649	1,630
Non-operating income		
Dividends income	231	232
Equity in earnings of affiliates	100	140
Other	236	169
Total non-operating income	569	542
Non-operating expenses		
Interest expenses	115	107
Foreign exchange loss	-	42
Other	41	25
Total non-operating expenses	156	174
Ordinary income	1,061	1,998
Extraordinary income		
Gain on sales of noncurrent assets	4	6
Gain on sales of investment securities	260	-
Other	-	0
Total extraordinary income	264	7
Extraordinary loss		
Loss on sales and retirement of noncurrent assets	12	14
Loss on valuation of investment securities	23	-
Other	-	1
Total extraordinary losses	36	16
Income before income taxes and minority interests	1,289	1,989
Income taxes-current	1,224	1,234
Income taxes-deferred	(667)	(463)
Total income taxes	556	770
Net income	732	1,218
Net income attributable to the noncontrolling interest	70	134
Net income attributable to owners of the parent	662	1,084

(Consolidated Quarterly Statements of Comprehensive Income)
(For the Three Months Ended June 30, 2016 and 2015)

(Millions of Yen)

	FY2016 (Apr. 1, 2015 – June 30, 2015)	FY2017 (Apr. 1, 2016 – June 30, 2016)
Net income	732	1,218
Other comprehensive income		
Valuation difference on available-for-sale securities	992	(273)
Deferred gains or losses on hedges	(32)	(505)
Foreign currency translation adjustment	(2,032)	(3,485)
Remeasurements of defined benefit plans	(12)	(2)
Share of other comprehensive income of associates accounted for using equity method	(4)	(193)
Total other comprehensive income	(1,090)	(4,461)
Comprehensive income	(357)	(3,242)
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	(219)	(2,800)
Comprehensive income attributable to noncontrolling interest	(138)	(441)

(3) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2015, to June 30, 2015)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	44,170	5,565	477	50,212	610	50,823	115	50,938
Intersegment	61	196	0	258	675	934	(934)	-
Total	44,231	5,761	478	50,471	1,286	51,757	(818)	50,938
Segment income (loss)	380	111	2	494	(20)	473	175	649

Notes:
1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
   (1) Net sales to external customers are income from real estate rent recognized by the Company.
   (2) Segment income (loss) comprises intersegment eliminations of ¥55 million and income of the Company not allocated to business segments of ¥119 million.
3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Non-current Assets, Goodwill, etc. by Reportable Segment

No items to report.

II. Period under Review (From April 1, 2016, to June 30, 2016)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	45,060	6,077	457	51,595	599	52,195	116	52,311
Intersegment	64	228	0	293	704	997	(997)	-
Total	45,124	6,306	457	51,888	1,304	53,192	(881)	52,311
Segment income	843	643	(24)	1,462	25	1,488	141	1,630

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.

2. Details of adjustment amounts are as follows.

(1) Net sales to external customers are income from real estate rent recognized by the Company.

(2) Segment income (loss) comprises intersegment eliminations of ¥58 million and income of the Company not allocated to business segments of ¥82 million.

3. Segment income (loss) has been adjusted to the operating loss of consolidated quarterly statements of income.

2. Matters concerning Changes to Reporting Segments

(Application of Practical Solution on a change in depreciation method due to Tax Reform 2016)

As stated in Change in Accounting Policy, in the three month period ended June 30, 2016, the Company applied Practical Solution on a change in depreciation method due to Tax Reform 2016, and changed the method of depreciation for structures and facilities attached to buildings acquired on and after April 1, 2016 from the declining-balance method to the straight-line method.

The impact of this change on segment income for the three month period ended June 30, 2016 is immaterial.

3. Information on Impairment Loss on Non-current Assets, Goodwill, etc. by Reportable Segment

No items to report.

平成29年3月期
第1四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the First Quarter Ended June 30, 2016

1. 宝ホールディングス(連結)
   Takara Holdings Inc. -Consolidated-
   グループ別要約損益計算書
   Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造グループ
   Takara Shuzo Group
   要約損益計算書
   Statements of Income (Summary)

3. タカラバイオグループ
   Takara Bio Group
   要約損益計算書
   Statements of Income (Summary)

4. 平成29年3月期第1四半期　参考資料
   Reference Data for the First Quarter Ended June 30, 2016

5. 6年間の財務サマリー(グループ別)
   Six-Year Financial Summary by Business Group

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

IR部 Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5194
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　IR部

Takara Holdings Inc.　Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5194

E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	平成28年3月期 第1四半期	平成29年3月期 第1四半期 Apr. 1, 2016 - Jun. 30, 2016		
	実績(a) FY2016 (1stQ) Actual (a)	実績(b) FY2017 (1stQ) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
宝酒造 グループ Takara Shuzo Group	44,231	45,124	892	102.0%
タカラバイオ グループ Takara Bio Group	5,761	6,306	544	109.5%
宝ヘルスケア Takara Healthcare Inc.	478	457	△ 20	95.8%
その他 Other, net	467	422	△ 45	90.3%
売上高 Net sales	50,938	52,311	1,372	102.7%
売上原価 Cost of sales	31,323	31,391	68	100.2%
売上総利益 Gross profit	19,615	20,919	1,303	106.6%
運送費、保管料 Transportation and storage	1,974	2,097	122	106.2%
広告宣伝費 Advertising	952	894	△ 57	93.9%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	8,169	8,370	200	102.5%
研究開発費 Research and development	1,103	1,045	△ 58	94.7%
管理費、その他 Other, net	6,765	6,881	116	101.7%
販売費及び一般管理費 SG&A expenses	18,966	19,289	323	101.7%
宝酒造 グループ Takara Shuzo Group	380	843	463	221.8%
タカラバイオ グループ Takara Bio Group	111	643	531	576.3%
宝ヘルスケア Takara Healthcare Inc.	2	△ 24	△ 26	―
その他 Other, net	155	167	12	107.9%
営業利益(△:損失) Operating income(Δ:loss)	649	1,630	980	251.0%
受取利息・配当金 Interest and Dividends income	292	280	△ 11	96.1%
その他営業外収益 Other, net	276	261	△ 14	94.7%
営業外収益 Non-operating income	569	542	△ 26	95.4%
支払利息 Interest and discounts expenses	115	107	△ 8	93.0%
その他営業外費用 Other, net	41	67	25	161.1%
営業外費用 Non-operating expenses	156	174	17	111.1%
経常利益(△:損失) Ordinary income(Δ:loss)	1,061	1,998	937	188.3%
特別利益 Extraordinary gain	264	7	△ 256	2.8%
特別損失 Extraordinary loss	36	16	△ 19	46.0%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	1,289	1,989	699	154.3%
法人税、住民税及び事業税 Current income taxes 法人税等調整額 Deferred income taxes	556	770	213	138.4%
四半期純利益(△:損失) Net income(Δ:loss)	732	1,218	486	166.4%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	70	134	64	191.2%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	662	1,084	422	163.7%
設備投資額(有形・無形) Capital expenditures	365	681	315	186.3%
減価償却費(有形・無形) Depreciation and Amortization	1,216	1,245	29	102.4%
のれん償却額 Amortization of goodwill	133	122	△ 11	91.6%

営業外収益 Non-operating income	受取利息48、受取配当金232、持分法による投資利益140、生命保険配当金63 など Interest income 48, Dividends income 232, Equity in earnings of affiliates 140, Dividend income of life insurance 63 etc.
営業外費用 Non-operating expenses	支払利息42、社債利息64、為替差損42 など Interest expenses 42, Interest on bonds 64, foreign exchange loss42 etc.
特別利益 Extraordinary gain	(前期:投資有価証券売却益260 など) (FY2016(1Q): Gain on sales of investment securities 260, etc.)
特別損失 Extraordinary loss	(前期:投資有価証券評価損23 など) (FY2016(1Q): Loss on valuation of investment securities 23, etc.)

2. 宝酒造グループ :Takara Shuzo Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成28年3月期 第1四半期	平成29年3月期 第1四半期 Apr. 1, 2016 - Jun. 30, 2016		
	実績(a) FY2016 (1stQ) Actual (a)	実績(b) FY2017 (1stQ) Actual (b)	増減(b−a) Change (b-a)	比(b/a) YOY% (b/a)
焼酎 Shochu	14,323	14,128	△ 194	98.6%
清酒 Sake	4,503	4,516	13	100.3%
ソフトアルコール飲料 Light-alcohol refreshers	6,876	7,300	423	106.2%
その他酒類 Other liquors	3,173	3,381	207	106.5%
本みりん Hon Mirin	3,332	3,464	132	104.0%
その他調味料 Other seasonings	2,103	2,259	156	107.4%
原料用アルコール等 Raw alcohol	1,902	1,769	△ 132	93.0%
海外日本食材卸 Japanese food wholesale business in overseas markets	4,646	5,300	654	114.1%
その他 Other	3,370	3,002	△ 367	89.1%
売上高 Net sales	44,231	45,124	892	102.0%
売上原価 Cost of sales	28,466	28,622	156	100.5%
売上総利益 Gross profit	15,764	16,501	736	104.7%
運送費、保管料 Transportation and storage	1,796	1,917	120	106.7%
広告宣伝費 Advertising	817	746	△ 70	91.4%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	7,927	8,131	203	102.6%
研究開発費 Research and development	81	85	3	104.2%
管理費、その他 Other, net	4,761	4,777	15	100.3%
販売費及び一般管理費 SG&A expenses	15,384	15,658	273	101.8%
営業利益（△：損失） Operating income(Δ:loss)	380	843	463	221.8%
営業外収益 Non-operating income	255	245	△ 10	96.0%
営業外費用 Non-operating expenses	104	79	△ 24	76.6%
経常利益（△：損失） Ordinary income(Δ:loss)	531	1,009	477	189.8%
特別利益 Extraordinary gain	3	4	0	122.5%
特別損失 Extraordinary loss	29	12	△ 17	42.5%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	505	1,001	495	198.0%
法人税、住民税及び事業税 Current income taxes	156	339	182	216.2%
法人税等調整額 Deferred income taxes				
四半期純利益（△：損失） Net income(Δ:loss)	349	662	313	189.7%
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	70	7	△ 63	10.6%
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	278	654	376	235.1%

設備投資額（有形・無形） Capital expenditures	273	422	148	154.5%
減価償却費（有形・無形） Depreciation and Amortization	765	749	△ 15	98.0%
のれん償却額 Amortization of goodwill	88	78	△ 9	89.1%

3. タカラバイオグループ :Takara Bio Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成28年3月期 第1四半期	平成29年3月期 第1四半期 Apr. 1, 2016 - Jun. 30, 2016		
	実績(a) FY2016 (1stQ) Actual (a)	実績(b) FY2017 (1stQ) Actual (b)	増減(b−a) Change (b-a)	比(b/a) YOY% (b/a)
研究用試薬 Research reagents	4,277	4,737	460	110.8%
理化学機器 Scientific instruments	415	509	93	122.6%
受託・その他 Contracted service and other	611	566	△ 45	92.5%
バイオ産業支援　計 Bioindustry	5,304	5,813	508	109.6%
遺伝子医療 Gene therapy	—	—	—	—
医食品バイオ AgriBio	457	493	35	107.9%
売上高 Net sales	5,761	6,306	544	109.5%
売上原価 Cost of sales	2,439	2,439	0	100.0%
売上総利益 Gross profit	3,322	3,866	544	116.4%
運送費、保管料 Transportation and storage	148	146	△ 2	98.3%
広告宣伝費 Advertising	24	24	0	100.8%
販売促進費 Sales promotion	215	214	△ 1	99.3%
研究開発費 Research and development	1,020	950	△ 70	93.1%
管理費、その他 Other, net	1,801	1,887	86	104.8%
販売費及び一般管理費 SG&A expenses	3,210	3,223	12	100.4%
バイオ産業支援　計 Bioindustry	991	1,456	465	146.9%
遺伝子医療 Gene therapy	△ 420	△ 373	46	—
医食品バイオ AgriBio	△ 46	△ 15	30	—
共通 Eliminations/Corporate	△ 413	△ 424	△ 10	—
営業利益（△：損失） Operating income(Δ:loss)	111	643	531	576.3%
営業外収益 Non-operating income	108	43	△ 65	39.8%
営業外費用 Non-operating expenses	2	32	30	1184.8%
経常利益（△：損失） Ordinary income(Δ:loss)	217	653	436	300.2%
特別利益 Extraordinary gain	0	2	2	829.5%
特別損失 Extraordinary loss	6	3	△ 2	60.1%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	211	652	440	308.4%
法人税、住民税及び事業税 Current income taxes	245	368	122	150.1%
法人税等調整額 Deferred income taxes				
四半期純利益（△：損失） Net income(Δ:loss)	△ 33	283	317	—
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	2	△ 1	△ 3	—
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	△ 36	285	321	—

設備投資額（有形・無形） Capital expenditures	90	211	120	232.6%
減価償却費（有形・無形） Depreciation and Amortization	392	436	43	111.2%
のれん償却額 Amortization of goodwill	44	43	△ 1	96.5%

4. 平成29年3月期第1四半期　参考資料 :Reference Data for the First Quarter Ended June 30, 2016

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	平成28年3月期 第1四半期	平成29年3月期 第1四半期 Apr. 1, 2016 - Jun. 30, 2016	
	実績(a) FY2016 (1stQ) Actual (a)	実績(b) FY2017 (1stQ) Actual (b)	前期差 Change(b-a)
米ドル： US dollar	119.17	115.33	△ 3.84
ポンド: Pound	180.48	165.01	△ 15.47
ユーロ: Euro	134.00	127.11	△ 6.89
人民元: Yuan	19.09	17.60	△ 1.49
100ウォン: 100 Won	10.83	9.60	△ 1.23
インドルピー: Rupee	1.92	1.71	△ 0.21
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	14.29	13.64	△ 0.65
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	87.44	82.18	△ 5.26

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2016(1stQ)
焼酎 Shochu	△ 2
清酒 Sake	△ 23
ソフトアルコール飲料 Light-alcohol refreshers	△ 0
その他酒類 Other liquors	△ 63
本みりん Hon Mirin	△ 6
その他調味料 Other seasonings	△ 4
原料用アルコール等 Raw alcohol	—
海外日本食材卸 Japanese food wholesale business in overseas markets	△ 339
その他 Other	—
宝酒造グループ　計 Net sales of Takara Shuzo Group	△ 439
研究用試薬 Research reagents	△ 214
理化学機器 Scientific instruments	△ 3
受託・その他 Contracted service and other	△ 14
バイオ産業支援　計 Bioindustry	△ 232
遺伝子医療 Gene Therapy	—
医食品バイオ AgriBio	—
タカラバイオグループ　計 Net sales of Takara Bio Group	△ 232
宝ホールディングス　計 Net sales of Takara Holdings Inc. -Consolidated-	△ 671

② 海外売上高比率の推移 :Change in overseas sales ratio

	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	平成29年3月期 第1四半期 FY2017 (1stQ)
宝酒造グループ Takara Shuzo Group	5.6%	7.7%	13.4%	15.1%	16.2%
タカラバイオグループ Takara Bio Group	47.4%	53.9%	59.8%	61.8%	62.9%
その他 Other	—	—	—	—	—
宝ホールディングス Takara Holdings Inc. -Consolidated-	9.1%	11.7%	17.6%	20.1%	21.6%

③ 海外主要子会社の業績 :Financial Result of major overseas subsidiaries

		平成28年3月期第1四半期累計実績 FY2016(1stQ) Actual		平成29年3月期 第1四半期累計実績 FY2017(1stQ) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	6,990	659	7,607	580
Takara Sake USA Inc.	百 万 円 :Millions of Yen	833	78	877	66
宝酒造食品	千 元 :Thousands of Yuan	11,595	289	9,763	Δ 355
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	221	5	171	Δ 6
トマーチン	千 ポ ン ド :Thousands of Pound	3,724	679	3,062	281
The Tomatin Distillery Co.,Ltd.	百 万 円 :Millions of Yen	672	122	505	46
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	2,757	1,003	4,525	1,740
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	328	119	521	200
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	25,585	2,965	31,352	3,436
FOODEX Group	百 万 円 :Millions of Yen	3,428	397	3,985	436
タザキフーズ	千 ポ ン ド :Thousands of Pound	6,795	555	8,035	732
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	1,226	100	1,325	120
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S.	千 ユ ー ロ :Thousands of Euro	4,120	419	4,884	672
Takara Bio Europe S.A.S.	百 万 円 :Millions of Yen	552	56	620	85
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟAB	千 SEK :Thousands of Sweden Krona	11,772	Δ 395	6,736	Δ 4,317
Takara Bio Europe AB	百 万 円 :Millions of Yen	168	Δ 5	91	Δ 58
宝生物工程(大連)	千 元 :Thousands of Yuan	56,614	19,690	75,439	32,071
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	1,080	375	1,327	564
宝日医生物技術(北京)	千 元 :Thousands of Yuan	22,307	498	26,043	560
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	425	9	458	9
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	1,955	230	2,023	247
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	211	24	194	23
タカラバイオDSSインド	千ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	50,833	4,219	46,587	Δ 434
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	97	8	79	Δ 0
タカラバイオUSA	千 US ドル :Thousands of US dollar	15,456	2,515	19,891	4,652
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	1,841	299	2,294	536

④ 宝酒造グループ 営業利益増減要因 :Factors of change in operating income of Takara Shuzo Group

(百万円 :Millions of Yen)

要因 Factors	対前期増減 Change from FY2016(1stQ)	内容 Detail
売上総利益の増減 (宝酒造単体) Change in Gross profit of TAKARA SHUZO CO.,LTD.	+668	数量差 +328 単価差 +339 Change in quantities +328 Change in unit price +339 ➢主な内訳 Breakdown 焼酎+30(数量差△89 単価差+120) Shochu +30 (Change in quantities △89 Change in unit price +120) 清酒+43(数量差+37 単価差+6) Sake +43 (Change in quantities +37 Change in unit price +6) ソフトアルコール飲料+237(数量差+195 単価差+41) Light-alcohol refreshers +237(Change in quantities +195 Change in unit price +41) 本みりん+105(数量差+65 単価差+40) Hon Mirin+105 (Change in quantities +65 Change in unit price +40) (参考)原価コストダウン +228 Reference :Cost reduction +228 ※上記数量差および単価差に含む *Included in changes above
販売費及び一般管理費の増減 (宝酒造単体) Change in SG&A expenses of TAKARA SHUZO CO.,LTD.	Δ 184	運送費の増加 △69 Change in Transportation and storage △69 広告宣伝費の減少 +65 Change in Advertising +65 販売促進費の増加 △212 Change in Sales promotion and allowance for s.p. △212
宝酒造単体 計 TAKARA SHUZO CO.,LTD.	+483	
その他の子会社における 営業利益の増減 Change in Operating income of other subsidiaries	Δ 20	海外日本食材卸会社 +67 ※のれん償却後 (フーデックス +59、コミンポート △16、タザキフーズ +24) Japanese food wholesale business in overseas markets +67 Foodex S.A.S. +59 Cominport Distribución S.L. △16 TAZAKI FOODS LTD. +24 *Include amortization of goodwil その他の海外子会社 △20 Other overseas subsidiaries △20 国内子会社 △48 Domestic subsidiaries △48 連結消去等 △19 Elimination of intra-company transactions,etc. △19
宝酒造グループ 計 Takara Shuzo Group	+463	

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown「+」and「△」, respectively

4. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		平成24年3月期 第1四半期 FY2012 (1stQ)	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	平成29年3月期 第1四半期 FY2017 (1stQ)	前期対比 Change from FY2016(1stQ) 増減 Change	比 YOY%
売上高	Net sales	48,866	47,349	46,953	50,025	50,938	52,311	1,372	102.7%
売上原価	Cost of sales	30,007	29,075	29,570	31,031	31,323	31,391	68	100.2%
（売上高原価率）	(Ratio to Net sales)	61.4%	61.4%	63.0%	62.0%	61.5%	60.0%	-1.5pt	–
売上総利益	Gross profit	18,859	18,273	17,382	18,994	19,615	20,919	1,303	106.6%
販売費及び一般管理費	SG&A expenses	17,194	17,212	17,624	17,811	18,966	19,289	323	101.7%
（売上高販管費率）	(Ratio to Net sales)	35.2%	36.4%	37.5%	35.6%	37.2%	36.9%	-0.4pt	–
営業利益（△：損失）	Operating income(Δ:loss)	1,664	1,061	Δ 241	1,182	649	1,630	980	251.0%
（売上高営業利益率）	(Ratio to Net Sales)	3.4%	2.2%	–	2.4%	1.3%	3.1%	+1.8pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	7,909	8,170	8,221	8,198	8,169	8,370	200	102.5%
（売上高販促費率）	(Ratio to Net sales)	16.2%	17.3%	17.5%	16.4%	16.0%	16.0%	-0.0pt	–
研究開発費	R&D expenses	701	737	792	792	1,103	1,045	Δ 58	94.7%
（売上高研究開発費率）	(Ratio to Net sales)	1.4%	1.6%	1.7%	1.6%	2.2%	2.0%	-0.2pt	–
設備投資額（有形・無形）	Capital expenditures	638	998	1,777	2,012	365	681	315	186.3%
減価償却費（有形・無形）	Depreciation and Amortization	1,061	999	996	1,012	1,216	1,245	29	102.4%
のれん償却額	Amortization of goodwill	69	68	75	116	133	122	Δ 11	91.6%

宝酒造グループ :Takara Shuzo Group

（百万円 :Millions of Yen）

		平成24年3月期 第1四半期 FY2012 (1stQ)	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	平成29年3月期 第1四半期 FY2017 (1stQ)	前期対比 Change from FY2016(1stQ) 増減 Change	比 YOY%
売上高	Net sales	44,118	42,291	41,978	44,370	44,231	45,124	892	102.0%
売上原価	Cost of sales	27,839	27,025	27,242	28,623	28,466	28,622	156	100.5%
（売上高原価率）	(Ratio to Net sales)	63.1%	63.9%	64.9%	64.5%	64.4%	63.4%	-0.9pt	–
売上総利益	Gross profit	16,278	15,266	14,735	15,746	15,764	16,501	736	104.7%
販売費及び一般管理費	SG&A expenses	14,781	14,680	14,869	14,916	15,384	15,658	273	101.8%
（売上高販管費率）	(Ratio to Net sales)	33.5%	34.7%	35.4%	33.6%	34.8%	34.7%	-0.1pt	–
営業利益（△：損失）	Operating income(Δ:loss)	1,496	585	Δ 134	830	380	843	463	221.8%
（売上高営業利益率）	(Ratio to Net sales)	3.4%	1.4%	–	1.9%	0.9%	1.9%	+1.0pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	7,694	7,942	7,977	7,970	7,927	8,131	203	102.6%
（売上高販促費率）	(Ratio to Net sales)	17.4%	18.8%	19.0%	18.0%	17.9%	18.0%	+0.1pt	–
設備投資額（有形・無形）	Capital expenditures	386	331	369	1,206	273	422	148	154.5%
減価償却費（有形・無形）	Depreciation and Amortization	763	703	683	705	765	749	Δ 15	98.0%
のれん償却額	Amortization of goodwill	37	37	43	85	88	78	Δ 9	89.1%

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		平成24年3月期 第1四半期 FY2012 (1stQ)	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	平成29年3月期 第1四半期 FY2017 (1stQ)	前期対比 Change from FY2016(1stQ) 増減 Change	比 YOY%
売上高	Net sales	3,823	4,104	4,170	4,779	5,761	6,306	544	109.5%
売上原価	Cost of sales	1,683	1,569	1,977	2,024	2,439	2,439	0	100.0%
（売上高原価率）	(Ratio to Net sales)	44.0%	38.2%	47.4%	42.4%	42.3%	38.7%	-3.6pt	–
売上総利益	Gross profit	2,140	2,535	2,192	2,754	3,322	3,866	544	116.4%
販売費及び一般管理費	SG&A expenses	2,188	2,360	2,551	2,689	3,210	3,223	12	100.4%
（売上高販管費率）	(Ratio to Net sales)	57.2%	57.5%	61.2%	56.3%	55.7%	51.1%	-4.6pt	–
営業利益（△：損失）	Operating income(Δ:loss)	Δ 48	175	Δ 358	65	111	643	531	576.3%
（売上高営業利益率）	(Ratio to Net sales)	–	4.3%	–	1.4%	1.9%	10.2%	+8.3pt	–
研究開発費	R&D expenses	608	646	704	703	1,020	950	Δ 70	93.1%
（売上高研究開発費率）	(Ratio to Net sales)	15.9%	15.7%	16.9%	14.7%	17.7%	15.1%	-2.6pt	–
設備投資額（有形・無形）	Capital expenditures	238	475	1,390	782	90	211	120	232.6%
減価償却費（有形・無形）	Depreciation and Amortization	263	263	271	269	392	436	43	111.2%
のれん償却額	Amortization of goodwill	31	31	32	30	44	43	Δ 1	96.5%

宝ヘルスケア :Takara Healthcare Inc.

（百万円 :Millions of Yen）

		平成24年3月期 第1四半期 FY2012 (1stQ)	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	平成29年3月期 第1四半期 FY2017 (1stQ)	前期対比 Change from FY2016(1stQ) 増減 Change	比 YOY%
売上高	Net sales	615	551	292	385	478	457	Δ 20	95.8%
売上原価	Cost of sales	406	355	133	188	241	204	Δ 37	84.5%
（売上高原価率）	(Ratio to Net sales)	66.0%	64.5%	45.6%	48.8%	50.5%	44.6%	-5.9pt	–
売上総利益	Gross profit	209	195	159	197	236	253	17	107.2%
販売費及び一般管理費	SG&A expenses	252	203	198	188	234	277	43	118.7%
（売上高販管費率）	(Ratio to Net sales)	41.1%	36.8%	67.9%	48.8%	49.0%	60.7%	+11.7pt	–
営業利益（△：損失）	Operating income(Δ:loss)	Δ 43	Δ 7	Δ 39	9	2	Δ 24	Δ 26	–
（売上高営業利益率）	(Ratio to Net sales)	–	–	–	2.4%	0.5%	–	–	–
ヘルスケア事業売上高	Net sales of Healthcare products	264	314	292	385	478	457	Δ 20	95.8%
設備投資額（有形・無形）	Capital expenditures	3	–	1	–	1	2	0	168.1%
減価償却費（有形・無形）	Depreciation and Amortization	2	2	0	0	0	1	0	140.7%